Neusignal Therapeutics

Neusignal Therapeutics is a biopharmaceutical company dedicated to developing treatments for Central Nervous System (CNS) diseases, with a primary focus on Alzheimer's disease. The company was founded in April 2022 by Dr. Shigeki Moriguchi, an Associate Professor at Tohoku University's Graduate School of Pharmaceutical Sciences. Dr. Moriguchi's research into dementia and neuronal calcium signaling at the university formed the scientific basis for the company's lead drug candidate. The company's CEO is Itaru Arimoto, Ph.D., who previously led the development and regulatory approval of the dementia drug donepezil at Eisai Co., Ltd.

Neusignal Therapeutics is advancing its lead candidate, NTX-083, an orally administered small molecule for Alzheimer's disease. The company's approach is based on a novel mechanism of action that aims to provide a first-in-class drug. Non-clinical studies have suggested that NTX-083 may improve both core cognitive symptoms and secondary psychiatric symptoms, while also acting as a disease-modifying agent. The company operates on patents transferred from Tohoku University and has completed non-clinical studies and GLP toxicology studies required for clinical trials. As of late 2025, Neusignal had initiated a Phase 1 clinical trial of NTX-083 in healthy adults and was preparing for a Phase 1b trial in Alzheimer's patients in the United States.

The company's business model is centered on the research, development, and eventual commercialization of its therapeutic pipeline. In January 2025, Neusignal Therapeutics announced it had secured a total of ¥2.25 billion in a Series A funding round. This comprised ¥1.15 billion from a third-party allocation of shares to new and existing investors and a ¥1.1 billion grant from the Japan Agency for Medical Research and Development (AMED). The funds are designated for advancing clinical trials and strengthening its development infrastructure for planned U.S. expansion. The investor roster includes firms such as First Track Initiative, Inc., Keio Innovation Initiative, Inc., and Mitsubishi UFJ Capital Co., Ltd.

Keywords: Alzheimer's disease, CNS disorders, dementia treatment, neurodegenerative disease, therapeutic drugs, small molecule drugs, clinical trials, biopharmaceutical, drug discovery, NTX-083, neuronal signaling, disease-modifying, cognitive improvement, psychiatric symptoms, Tohoku University, Japan Agency for Medical Research and Development, Series A funding, venture capital